Literature DB >> 28360200

Toward neuroprotective treatments of Parkinson's disease.

Kwang-Soo Kim1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28360200      PMCID： PMC5393211          DOI： 10.1073/pnas.1703362114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  20 in total

1.  Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.

Authors:  Athanasios D Spathis; Xenophon Asvos; Despina Ziavra; Theodoros Karampelas; Stavros Topouzis; Zoe Cournia; Xiaobing Qing; Pavlos Alexakos; Lisa M Smits; Christina Dalla; Hardy J Rideout; Jens Christian Schwamborn; Constantin Tamvakopoulos; Demosthenes Fokas; Demetrios K Vassilatis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-27       Impact factor: 11.205

Review 2.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

3.  4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery.

Authors:  Chun-Hyung Kim; Pierre Leblanc; Kwang-Soo Kim
Journal:  Expert Opin Drug Discov       Date:  2016-03-07       Impact factor: 6.098

4.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

5.  Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation.

Authors:  M Maira; C Martens; A Philips; J Drouin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

Review 6.  Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates.

Authors:  Timothy J Collier; Nicholas M Kanaan; Jeffrey H Kordower
Journal:  Nat Rev Neurosci       Date:  2011-05-18       Impact factor: 34.870

Review 7.  Priorities in Parkinson's disease research.

Authors:  Wassilios G Meissner; Mark Frasier; Thomas Gasser; Christopher G Goetz; Andres Lozano; Paola Piccini; José A Obeso; Olivier Rascol; Anthony Schapira; Valerie Voon; David M Weiner; François Tison; Erwan Bezard
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

8.  Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway.

Authors:  Sangmi Chung; Amanda Leung; Baek-Soo Han; Mi-Yoon Chang; Jung-Il Moon; Chun-Hyung Kim; Sunghoi Hong; Jan Pruszak; Ole Isacson; Kwang-Soo Kim
Journal:  Cell Stem Cell       Date:  2009-12-04       Impact factor: 24.633

9.  Dopamine neuron agenesis in Nurr1-deficient mice.

Authors:  R H Zetterström; L Solomin; L Jansson; B J Hoffer; L Olson; T Perlmann
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

10.  Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression.

Authors:  Nikolaos Volakakis; Katarina Tiklova; Mickael Decressac; Maria Papathanou; Bengt Mattsson; Linda Gillberg; André Nobre; Anders Björklund; Thomas Perlmann
Journal:  J Neurosci       Date:  2015-10-21       Impact factor: 6.167
View more
  7 in total

Review 1.  Closing the loop for patients with Parkinson disease: where are we?

Authors:  Hazhir Teymourian; Farshad Tehrani; Katherine Longardner; Kuldeep Mahato; Tatiana Podhajny; Jong-Min Moon; Yugender Goud Kotagiri; Juliane R Sempionatto; Irene Litvan; Joseph Wang
Journal:  Nat Rev Neurol       Date:  2022-06-09       Impact factor: 44.711

2.  Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.

Authors:  Helen Schmitz-Steinkrüger; Catharina Lange; Ivayla Apostolova; Franziska L Mathies; Lars Frings; Susanne Klutmann; Sabine Hellwig; Philipp T Meyer; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-31       Impact factor: 9.236

3.  PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function.

Authors:  Sreekanth Rajan; Yongwoo Jang; Chun-Hyung Kim; Woori Kim; Hui Ting Toh; Jeha Jeon; Bin Song; Aida Serra; Julien Lescar; Jun Yeob Yoo; Serap Beldar; Hong Ye; Congbao Kang; Xue-Wei Liu; Melissa Feitosa; Yeahan Kim; Dabin Hwang; Geraldine Goh; Kah-Leong Lim; Hye Min Park; Choong Hwan Lee; Sungwhan F Oh; Gregory A Petsko; Ho Sup Yoon; Kwang-Soo Kim
Journal:  Nat Chem Biol       Date:  2020-05-25       Impact factor: 15.040

4.  Treatment Patterns in Patients with Incident Parkinson's Disease in the United States.

Authors:  Richard Houghton; Frank Boess; Lynne Verselis; Yingjie Ding; Rita Freitas; Niculae Constantinovici; Rose Ong
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

Review 5.  Postural Instability in Parkinson's Disease: A Review.

Authors:  Bhavana Palakurthi; Sindhu Preetham Burugupally
Journal:  Brain Sci       Date:  2019-09-18

Review 6.  The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis.

Authors:  Seong Gak Jeon; Anji Yoo; Dong Wook Chun; Sang Bum Hong; Hyunju Chung; Jin-Il Kim; Minho Moon
Journal:  Aging Dis       Date:  2020-05-09       Impact factor: 6.745

Review 7.  Potent synthetic and endogenous ligands for the adopted orphan nuclear receptor Nurr1.

Authors:  Yongwoo Jang; Woori Kim; Pierre Leblanc; Chun-Hyung Kim; Kwang-Soo Kim
Journal:  Exp Mol Med       Date:  2021-01-21       Impact factor: 8.718
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.